Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.</p>

Kaydedildi:
Detaylı Bibliyografya
Yazar: Amir T. Fathi (15313195) (author)
Diğer Yazarlar: Haesook T. Kim (15313198) (author), Robert J. Soiffer (15313201) (author), Mark J. Levis (15313204) (author), Shuli Li (15313207) (author), Annette S. Kim (15117505) (author), Zachariah DeFilipp (15313210) (author), Areej El-Jawahri (15313213) (author), Steve L. McAfee (15313216) (author), Andrew M. Brunner (15313219) (author), Philip C. Amrein (15313222) (author), Alice S. Mims (11016414) (author), Laura W. Knight (15313225) (author), Devon Kelley (15313228) (author), AJ S. Bottoms (15313231) (author), Lindsey H. Perry (15313234) (author), Jonathan L. Wahl (15313237) (author), Jennifer Brock (15313240) (author), Elayne Breton (15313243) (author), Dylan M. Marchione (14935655) (author), Vincent T. Ho (15313246) (author), Yi-Bin Chen (15313249) (author)
Baskı/Yayın Bilgisi: 2025
Konular:
Cancer
Therapeutic Research and Development
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Drug Targets
Oncoprotein & tumor suppressor drug targets
Hematological Cancers
Leukemias
Immunotherapy
Stem cell transplantation
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller